Argenica Therapeutics Ltd
ASX:AGN
Prices of ASX stocks are not being updated. The latest AGN price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Argenica Therapeutics Ltd (AGN) under the Base Case is AUD per share.
Compared with the last price of 0.125 AUD on Oct 14, the stock appears .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Argenica Therapeutics Does
Argenica Therapeutics is a clinical-stage biotechnology company focused on drugs that protect brain cells after a stroke or other acute brain injury. Its lead work centers on peptide-based medicines designed to reduce damage caused when the brain is cut off from oxygen or blood flow. In simple terms, the company is trying to turn a lab-made molecule into a treatment that can help preserve brain function after a major neurological event.
- Headquarters
- Australia AU
- IPO date
- Jun 11, 2021
Earnings Waterfall
Argenica Therapeutics Ltd
What is the Intrinsic Value of one AGN stock?
The intrinsic value for Argenica Therapeutics Ltd (AGN) under the Base Case is AUD.
Is AGN stock undervalued or overvalued?
Compared with the last price of 0.125 AUD on Oct 14, the stock appears .
